DALLAS, September 3, 2014 /PRNewswire/ --
This Age-Related Macular Degeneration EpiCast report forecasts that the total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of AMD, followed by Japan. This epidemiological analysis is supported by the use of total prevalence data from epidemiological studies published in peer-reviewed journals. Epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of AMD. Epidemiologists segmented AMD by stages (early AMD and late AMD, and the late AMD subtypes: dry AMD and wet AMD), which allows for a meaningful comparison of the disease populations between markets.
The EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023 provides an overview of the risk factors, co morbidities, and the global and historical trends for AMD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AMD segmented by sex and age (50-59 years, 60-69 years, 70-79 years, and =80 years) in these markets. Additionally, GlobalData epidemiologists provide the total prevalent cases of AMD segmented by AMD stages: early AMD and late AMD, as well as the late AMD subtypes: dry AMD and wet AMD.
Age-related macular degeneration (AMD) is a progressive eye condition caused by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly in the developed countries. In addition to the high prevalence of the condition, AMD is associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual. AMD is classified into two stages: early AMD and late AMD. Late AMD is the advanced stage of AMD, which is further subclassified as dry AMD (geographic atrophy) and wet AMD (neovascular).
The AMD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy (Order a copy of this report athttp://www.reportsnreports.com/Purchase.aspx?name=297297 )
- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
List of Tables provided in this research include:
Table 1: Risk Factors and Comorbidities for AMD 8
Table 2: Diagnostic Criteria for AMD 11
Table 3: 7MM, Sources of AMD Prevalence Data 12
Table 4: 7MM, Total Prevalent Cases of AMD, Ages =50 Years, Both Sexes, N, 2013-2023 18
Table 5: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013 20
Table 6: 7MM, Total Prevalent Cases of AMD, by Sex, Ages =50 Years, N (Row %), 2013 22
Table 7: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age =50 Years, N (Row %), 2013 25
Table 8: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age =50 Years, N (Row %), 2013 27
List of Figures provided in EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023 cover:
Figure 1: 7MM, Total Prevalent Cases of AMD, Ages =50 Years, Both Sexes, N, 2013 and 2023 5
Figure 2: 7MM, Total Prevalent Cases of AMD, Ages =50 Years, Both Sexes, N, 2013-2023 19
Figure 3: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013 21
Figure 4: 7MM, Total Prevalent Cases of AMD, by Sex, Ages =50 Years, N, 2013 23
Figure 5: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age =50 Years, by Sex, 2013 24
Figure 6: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age =50 Years, N, 2013 26
Figure 7: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age =50 Years, N, 2013 28
Explore more reports on pharmaceuticals market as well as medical devices industry at http://www.reportsnreports.com/market-research/medical-devices/ .
ReportsnReports.com is an online market research reports library of 450,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on: